U

United Medical Research Institute | Inglewood, CA

Research site

(Unclaimed)

Location

431-433 North Prairie Avenue, Inglewood, California, United States of America

Site insights

Top conditions

Top treatments

Latanoprost

AR-12286

AGN-190584

KPI-121

AR-13324

Netarsudil

ISV-502

K-321

PG286

PG043

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 28 total trials

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (STRIVE)

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-...

Enrolling

Thyroid Eye Disease

Drug: VRDN-001 10 mg/kg

Drug: VRDN-001 3 mg/kg

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling

Open-angle Glaucoma

Ocular Hypertension

Other: Sham Administration

Drug: AGN-193408 SR

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting

Glaucoma

Ocular Hypertension

Drug: Rhopressa®

Drug: T4090 0.3%

Next Generation Rocklatan

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Enrolling

Open Angle Glaucoma

Ocular Hypertension

Drug: AR-17043 Ophthalmic Solution

Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution